



**Contact:** Yuri Nikolsky  
**Location:** 169 Saxony Rd, #104  
**Email:** [yuri@genego.com](mailto:yuri@genego.com)  
**Tel:** (858) 756 7996  
**Website:** <http://www.genego.com>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
 National Institutes of Health



National Institutes of Health Commercialization Assistance Program  
 (NIH-CAP)

## Company Profile

**Industry Sector:** Biomarkers

**Company Overview:** Using its proprietary data mining technology, GeneGo has discovered and validated a set of gene expression biomarkers which divide breast cancer patients into clinically distinct groups (clusters). Every group feature differential expression of certain genes, clinical outcome and response to treatment. The Company now conducts a large retrospective validation study with Mayo Clinic, followed by product development and seeking FDA approval.

**Target Market(s):** Major hospitals and individual oncologists worldwide.

## Key Value Drivers

**Technology:** GeneGo developed a state-of-the art proprietary “systems reconstruction” technology for the analysis of high-throughput biological data. Disease-specific biomarkers discovery is a primary application of this technology. As soon as the set of markers is determined, they proceed through validation studies and product development phases. GeneGo technology is applicable for most of other cancers

**Competitive Advantage:** GeneGo breast cancer biomarkers over-perform the existing multi-variant genetic tests.

**Plan & Strategy:** seeking equity funding for product development , FDA approval and marketing

\*Technology funded by two NCI grants and being commercialized under the NIH-CAP

## Management

### Leadership:

Yuri Nikolsky, CEO  
 Tatiana Nikolskaya, President, Chief Scientific Officer  
 Andrej Bugrim, Chief Operating Officer  
 Julie Bryant, VP Business Development

## Product Pipeline

